Big consulting groups like to publish big reports on big topics, to establish their authority and expertise, and of course to impress potential clients with how smart and visionary they are. The glossy PDFs have big titles, and are punctuated by bold statements about industry transformations.
Some of those in favor of relaxed reimportation often argue that the drug industry is fear mongering when it points to potential safety problems with drugs or ingredients sourced from abroad. "Be afraid, be very afraid.
Busy and eventful week. Michele's on her way to Ireland to visit biotech and pharma labs, and Paul had nice interviews with AstraZeneca's CEO David Brennan and former House majority leader Dick Gephardt.
Any crime covered by the press inspires a wave of copycats. So, it seems, the global heparin supply chain will have to be closely monitored for some time. Both 2-D NMR and capillary electrophoresis have been recognized as the best ways to assess the purity of heparin.
On Monday afternoon, a manufacturing and operations discussion group focused on the topic of global competition. Session chair Julian Wilkins, Vice President of PharmaConsult US, Inc. and a part-time professor of Pharmaceutical Manufacturing at Stevens Institute set the stage with an introduction spelling out the issues and challenges.
The prospect of California's e-pedigree and drug serialization legislation being pushed back to 2015 (from 2009, then 2011) has the industry breathing a sigh of relief, or is it a sigh of frustration? Drug Channel's Adam Fein, back from his self-imposed blog-cation, weighs in.
The California state assembly has passed SB 1307, a measure that sponsor Sen. Mark-Ridley Thomas says is designed to ensure patient safety, but will in actuality yet again push back the proposed compliance date for drug manufacturers and distributors to meet electronic pedigree requirements to 2015--rather than the 2011 (and...
At the American Chemical Society national conference last weekend, Rensselaer Polytechnic researcher Dr. Robert Linhart announced that his team may have built the first fully synthetic heparin. Whether or not you believe that the possibility of another contamination crisis of natural raw heparin exists, the potential for a heparin supply...
At a meeting at DIA in Boston yesterday, Mike Svinte, President of Global Life Sciences at IBM provided a sneak peek and insights into a new report probing CEO challenges and concerns and their implications. The report, which is due to be released next month, will distill interviews with more...
Ever see the old Abbott and Costello "who's on first" baseball routine? "I don't know" was on third base. Pharma is not the only industry that suffers from less-than-perfect supply chain risk management, as Juran Institute CEO Joe De Feo pointed out in a recent audio interview.